Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Bergman

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Pharmacology & Therapeutics|September 29, 2000
Basis for effective combination cancer chemotherapy with antimetabolitesG J Peters, C L van der Wilt, C J van Moorsel, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell linesC J van Moorsel, G Veerman, V W Ruiz van Haperen, et al.
British Journal of Cancer|June 12, 2003
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell linesA M Bergman, H M Pinedo, I Talianidis, et al.
Prostate Cancer and Prostatic Diseases|October 16, 2019
Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancerM van Nuland, S L Groenland, A M Bergman, et al.
Biochemical Pharmacology|March 24, 2004
Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell linesA M Bergman, C M Kuiper, D A Voorn, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Mechanisms of synergism between gemcitabine and cisplatinC J van Moorsel, G Veerman, J B Vermorken, et al.
Biochemical Pharmacology|May 2, 2001
Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell linesA M Bergman, B Munch-Petersen, P B Jensen, et al.
Nucleosides, Nucleotides & Nucleic Acids|October 27, 2006
Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunitsK Smid, A M Bergman, P P Eijk, et al.
Biochemical Pharmacology|February 5, 1999
Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinaseA M Bergman, H M Pinedo, A P Jongsma, et al.
Biochimica Et Biophysica Acta|March 4, 2000
Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell linesC J van Moorsel, A M Bergman, G Veerman, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Pharmacology & Therapeutics|September 29, 2000
Basis for effective combination cancer chemotherapy with antimetabolitesG J Peters, C L van der Wilt, C J van Moorsel, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell linesC J van Moorsel, G Veerman, V W Ruiz van Haperen, et al.
British Journal of Cancer|June 12, 2003
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell linesA M Bergman, H M Pinedo, I Talianidis, et al.
Prostate Cancer and Prostatic Diseases|October 16, 2019
Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancerM van Nuland, S L Groenland, A M Bergman, et al.
Biochemical Pharmacology|March 24, 2004
Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell linesA M Bergman, C M Kuiper, D A Voorn, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Mechanisms of synergism between gemcitabine and cisplatinC J van Moorsel, G Veerman, J B Vermorken, et al.
Biochemical Pharmacology|May 2, 2001
Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell linesA M Bergman, B Munch-Petersen, P B Jensen, et al.
Nucleosides, Nucleotides & Nucleic Acids|October 27, 2006
Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunitsK Smid, A M Bergman, P P Eijk, et al.
Biochemical Pharmacology|February 5, 1999
Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinaseA M Bergman, H M Pinedo, A P Jongsma, et al.
Biochimica Et Biophysica Acta|March 4, 2000
Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell linesC J van Moorsel, A M Bergman, G Veerman, et al.
Pageof 5